Human epidermal growth factor receptor 2 (HER2)-directed treatment using trastuzumab has shown clinical benefit in HER2-positive gastric cancer. Clinical trials using lapatinib in HER2-positive gastric cancer are also currently underway. As with other molecularly targeted agents, the emergence of acquired resistance to HER2-directed treatment is an imminent therapeutic problem for HER2-positive gastric cancer. In order to investigate the mechanisms of acquired resistance to HER2-directed treatment in gastric cancer, we generated lapatinib-resistant gastric cancer cell lines (SNU216 LR) in vitro by chronic exposure of a HER2-positive gastric cancer cell line (SNU216) to lapatinib. The resultant SNU216 LR cells were also resistant to gefitinib, cetuximab, trastuzumab, afatinib and dacomitinib. Interestingly, SNU216 LR cells displayed an epithelial-mesenchymal transition (EMT) phenotype and maintained the activation of MET, HER3, Stat3, Akt and mitogen-activated protein kinase signaling in the presence of lapatinib. Using gene expression arrays, we identified the upregulation of a variety of EMT-related genes and extracellular matrix molecules, such as Testican-1, in SNU216 LR cells. We showed that the inhibition of Testican-1 by small interfering RNA decreased Testican-1-induced, MET-dependent, downstream signaling, and restored sensitivity to lapatinib in these cells. Furthermore, treatment with XAV939 selectively inhibited b-catenin-mediated transcription and Testican-1-induced EMT signaling, leading to G1 arrest. Taken together, these data support the potential role of EMT in acquired resistance to HER2-directed treatment in HER2-positive gastric cancer, and provide insights into strategies for preventing and/or overcoming this resistance in patients.
INTRODUCTION
Overexpression of human epidermal growth factor receptor 2 (HER2) in human gastric cancer, particularly in the advanced stages of disease, correlates with aggressive tumor growth and poor prognosis. Moreover, HER2 positivity was shown to be higher in the intestinal compared with diffuse types of cancer. Thus, HER2 is emerging as an important therapeutic target in gastric cancer. [1] [2] [3] Recently, ToGA clinical trial comparing the effect of combined chemotherapy and trastuzumab versus chemotherapy alone in patients with HER2-positive, advanced gastric cancer, showed clinical benefits in terms of overall survival, progression-free survival and response rate. 4 The antitumor activity of lapatinib, an epidermal growth factor receptor (EGFR) and HER2 dual tyrosine kinase inhibitor (TKI), has also been examined in gastric cancer cells. 5, 6 Currently, a phase III clinical trial comparing the effect of combined lapatinib and chemotherapy versus chemotherapy alone in HER2-positive patients with gastric cancer is ongoing. 7 Although overexpression of HER2 correlates with sensitivity to growth inhibition by lapatinib, not all cells overexpressing HER2 respond to lapatinib, 8 and resistance has been observed in a subset of patients following chronic exposure. The factors that confer primary or acquired resistance to lapatinib are not well characterized.
Recent studies have shown that resistance to EGFR-TKI in nonsmall cell lung cancer cell lines, correlates with epithelialmesenchymal transition (EMT) that affects cell-cell contacts. [9] [10] [11] [12] [13] [14] EMT is a unique process whereby epithelial cells undergo remarkable morphological changes, characterized by a transition from an epithelial cobblestone to an elongated mesenchymal phenotype, leading to increased motility and invasion. EMT progression is characterized by the loss of proteins involved in cell junctions, such as E-cadherin, and the expression of mesenchymal markers such as Vimentin and Snail. Non-small cell lung cancer cells acquiring a mesenchymal phenotype may therefore be resistant to TKI inhibition, as mesenchymal-like cells are capable of bypassing EGFR signaling, acquiring alternative routes of proliferative and survival signaling. For this to occur, extracellular matrix (ECM) molecules or membrane receptors must cooperate to specify these alternative signaling pathway(s) or to allow synergistic or antagonistic relationships, facilitating the communication of cancer cells with diverse extracellular cues. EMT is a dynamic process triggered by the interplay of several extracellular signals, including collagen. Many signaling pathways, including the Wnt/b-catenin, transforming growth factor-b, Hedgehog and integrin pathways are critical for EMT induction. 15, 16 However, the exact mechanism underlying the acquisition of the EMT phenotype in EGFR-TKI-resistant lung cancer cells remains unknown. Testican-1 was first defined as an unnamed chondroitin/ heparan sulfate proteoglycan in seminal plasma. 17 Testican-1 is a component of the ECM, with predicted roles in cell adhesion and migration. Initially, it was thought that Testicans may contribute to the proteoglycan-rich ECM of the brain and have a role in neurogenesis. Furthermore, overexpression of Testican has been reported in the prostate, pancreatic and hepatocellular carcinoma, in addition to gastric neuroendocrine tumors. [18] [19] [20] [21] However, the biological function of Testicans has not been extensively explored in cancer. We recently demonstrated that Testican-1-induced EMT signaling confers resistance to lapatinib.
In this study, we established lapatinib-resistant cell lines from HER2-positive, lapatinib-sensitive, SNU216 human gastric cancer cells. We demonstrate that increased Testican-1 induces EMT, representing a novel mechanism of resistance to lapatinib and trastuzumab. Inhibition of EMT by XAV939 selectively inhibited bcatenin-mediated transcription, restoring lapatinib sensitivity to these cells. Testican-1 deprivation or inhibition of the b-catenin pathway, restored lapatinib sensitivity by downregulating EMT signaling. These data support the development of novel, therapeutic approaches for treating HER2-positive gastric cancer. Furthermore, these data support a potential role of EMT transition in acquired resistance to HER2-directed treatment in HER2-positive gastric cancer, providing unique insights into strategies for preventing and overcoming disease resistance.
RESULTS
Activation of c-MET and HER3 confers acquired resistance to lapatinib-sensitive HER2-positive gastric cancer cells To explore the mechanisms of lapatinib resistance, we generated lapatinib-resistant gastric cancer cell lines using HER2-positive, lapatinib-hypersensitive SNU216 cells. Cells were exposed to increasing concentrations of lapatinib for 8 months, and singlecell clones were isolated from a pool of resistant cells (SNU216 LR) (full clones) to generate the resultant cell lines, SNU216 LR4-LR10 (7 clones), which displayed resistance to lapatinib in vitro (half-maximum inhibitory concentrations, IC 50 410 mmol/l; Figure 1a ). The phosphorylation status of HER family kinases and downstream targets of Stat, phosphatidylinositol 3-kinase/Akt and MEK signaling were determined for SNU216 and SNU216 LR cell lines. Treatment of parental SNU216 cells with lapatinib markedly inhibited tyrosine phosphorylation of EGFR, HER2 and HER3 in addition to Stat3, Akt and mitogen-activated protein kinase (MAPK). In contrast, phosphorylation of these proteins persisted at higher levels in lapatinib-resistant SNU216 LR cell lines following treatment (Figure 1b) . We next investigated whether aberrant activation of other receptors may have a role in mediating lapatinib resistance. We performed a phospho-receptor tyrosine kinase (phosphoreceptor tyrosine kinase) array to compare the effects of lapatinib on the phosphorylation of 42 receptor tyrosine kinases in SNU216 and SNU216 LR cells (full clones) (Figure 1c) . In SNU216 LR cells, EGFR, HER2, HER3 and MET were all phosphorylated, and phosphorylation persisted following lapatinib treatment, compared with parental cells. These results were confirmed using additional resistant clones (LR4, LR6 and LR7) and other resistant cells (N87 LR1-LR2; Supplementary Figures S1a and b) . Furthermore, we also observed that total levels of HER3 and MET were elevated in resistant clones (Figure 1d ). Previous studies have shown that acquired resistance to EGFR TKIs, such as erlotinib or gefitinib, is associated with a secondary mutation or MET amplification in nonsmall cell lung cancer. 22 Analysis of MET copy number in SNU216 LR lapatinib-resistant cells revealed no amplification compared with parental SNU216 cells. Furthermore, genomic DNA sequence analysis of the HER2 kinase domain in SNU216 and SNU216 LR cell lines revealed no mutations (data not shown). Taken together, these data suggest that the activation of c-MET and HER3 confers acquired resistance to lapatinib-sensitive, HER2-positive gastric cancer cells via persistent activation of Stat3, Akt and MAPK, the main downstream signaling effectors of EGFR and HER2.
Lapatinib-resistant cell lines are resistant to growth inhibition by HER-targeted inhibitors Next, we used MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays to assess the ability of HER-targeted inhibitors, gefitinib (an EGFR TKI), afatinib (an irreversible EGFR and HER2 TKI), dacomitinib (a pan-HER TKI), cetuximab (an EGFR monoclonal antibody) and trastuzumab (a HER2 monoclonal antibody), and to inhibit the growth of lapatinib-resistant clones ( Figure 2a ). We previously reported that these HER-targeted inhibitors (except cetuximab) are active in HER2-positive SNU216 gastric cancer cells. 5, 7, 23, 24 IC 50 of gefitinib, afatinib, dacomitinib on lapatinib-resistant cell lines (LR4, LR5 and LR6) were 500-fold higher against the parental cells. Moreover, the lapatinib-resistant clones were also resistant to growth inhibition by trastuzumab, compared with parental cells. In contrast, the inhibitory effect of cetuximab was similar in both parental and resistant clones. To further confirm these observations, we next assessed the levels of total and phosphorylated Stat3, Akt and MAPK (Figure 2b ). We observed that the phosphorylation status of Stat3, Akt and MAPK tended to be higher in SNU216 LR4 cells compared with parental cells. However, no significant differences in Stat3, Akt and MAPK phosphorylation were observed between SNU216 cells and SNU216 LR4 clones, following treatment with HER-targeted inhibitors. These results were confirmed in all lapatinib-resistant cell lines (data not shown). Table S1 , Po0.005) identified enrichment of several, interesting networks/pathways including those involved in cell cycle, regulation of apoptosis, focal adhesion, ECM-receptor interaction, immune response, leukocyte activation, antigen progression and presentation and leukocyte migration (Supplementary Figure S3) . However, one of the most striking patterns emerging from these analyses involved genes implicated in EMT, including genes required for extracellular matrix (Testican-1 and Timp3), EMT (transforming growth factor-a, Smad3, Tgm2, Twist1 and Foxm1), migration (COL18A1, ITGA6, FAS and FYN), and cell-cycle associated genes ( Figure 3a ). All genes in Figure 3a had statistical significance at the cutoff of Po0.005. Differential expression of EMT-associated genes (Vimentin, Twist1, Snail and b-catenin) and Testican-1, which was highly differentially expressed, was confirmed by quantitative reverse-transcription PCR (RT-PCR) using several resistant clones (Figure 3b ; Supplementary Figure S4) . We next analyzed protein levels of the epithelial marker, E-cadherin, and the mesenchymal marker, Vimentin, in three resistant clones. These analyses revealed that parental cell lines expressed E-cadherin, whereas resistant clones expressed high levels of Vimentin, confirming the gene expression and RT-PCR results. We also confirmed the increase in Testican-1 and b-catenin at the protein level in LR cell lines (LR4, LR6 and LR7; Figure 3c ). Interestingly, b-catenin levels were increased in LR4 cells, even though this is an epithelial marker. 15 Furthermore, the LR cells displayed an elongated and irregular fibroblastoid morphology. In contrast, parental cells displayed a rounded shape, typical of an epithelial cobblestone appearance, and these cells grew in clusters (Supplementary Figure S5) . These morphological changes suggest that LR cells have undergone EMT, as reported previously. 12 To further confirm the EMT of LR cells, we also investigated cell migration. As we expected, parental cells were less migratory than LR cells (Figure 3d) . Our results clearly demonstrate upregulation of EMT signaling in lapatinib-resistant cells. Taken together, these data indicate that EMT signaling may have a crucial role in lapatinib resistance in this cell model. Lapatinib resistance is reduced via the suppression of Testican-1 To determine whether Testican-1-induced EMT signaling underlies acquired resistance to lapatinib, we examined whether inhibition Inhibition of WNT/b-catenin signaling restores sensitivity to lapatinib Previously, we showed that the silencing of Testican-1 inhibits activated MET and HER3, and also leads to a decrease in the EMT regulators, Vimentin and b-catenin. WNT/b-catenin signaling is involved in EMT induction during tumor progression and converts polarized epithelial cells into motile, invasive cells. 25, 26 On the basis of this, we reasoned that the inhibition of WNT/b-catenin may restore lapatinib sensitivity caused by Testican-1-induced EMT signaling. To test this hypothesis, we investigated the effect of combined treatment with lapatinib and XAV939 on the growth of LR cells. XAV939 is a small-molecule inhibitor for the WNT/bcatenin pathway. 27 As shown in Figures 5a and b , treatment of cells with this drug combination had a greater inhibitory effect on cell growth compared with treatment with single-agent XAV939 in LR4 cells. XAV939 enhanced the inhibitory effect of lapatinib on cell growth in a dose-responsive manner. We next investigated cell cycle, following staining of cells with the DNA-intercalating dye, propidium iodide. The sensitivity of LR cells to lapatinib may result from cell cycle arrest at specific phases. As shown in Figure 5c , no significant change in cell cycle distribution was detected in cells treated with XAV939 alone. However, XAV939 increased the proportion of cells in the G1 phase of lapatinibtreated cells. We next examined the levels of total and phosphorylated Stat3, Akt, MAPK, b-catenin, cyclin D and p27 in LR4 cells (Figure 5d ). Treatment with lapatinib or XAV939 alone had no effect of inhibition detected to inhibit a phosphorylation of Akt and MAPK with decrease of the expression of cell cycle regulatory molecules examined. However, combined treatment with XAV939 and lapatinib led to a significant decrease in phosphorylated Stat3, Akt and MAPK. Cyclin D was also decreased after treatment with combination therapy, whereas the cell cycle inhibitor, p27, was increased. Taken together, these data show that combined treatment with lapatinib and XAV939 significantly inhibits the growth of lapatinib-resistant SNU216 LR4 cells.
DISCUSSION
In this study, we identify a novel, molecular mechanism of acquired resistance to lapatinib in HER2-positive gastric cancer cells. We established lapatinib-resistant cells from SNU216 HER2-positive gastric cancer cells in vitro, and characterized seven independent clones. In addition to displaying lapatinib resistance, these cell lines were also resistant to other HER-targeted agents, including trastuzumab (Figure 1b) . Our data provide strong evidence that increased EMT signals confer acquired resistance to lapatinib in this model system. This mechanism of lapatinib resistance has not been previously identified in a HER2-positive gastric cancer model, although HER2 TKI-acquired resistant cell lines have been reported in a HER2-positive breast cancer model. [28] [29] [30] To date, there is evidence to indicate that resistance to HER2-targeted therapy in breast cancer cells is attributed to cross-talk with insulin-like growth factor receptor I, 31 PTEN mutation or loss of heterozygosity, [32] [33] [34] depression of FOXO3a with increased estrogen receptor transcriptional activity, 35, 36 increased membrane localization of HER3 37 and extracellular domain shedding resulting in p95. [38] [39] [40] The resistance has also been attributed to the contribution of other membrane receptors or downstream effector(s). Recently, lapatinib resistance in BT474 human breast cancer cells, which are estrogen receptor-positive, progesterone receptor-positive and HER2-positive, was shown to be the result of AXL activation. It was suggested that this may represent an alternative pathway for proliferation, capable of bypassing the HER2 signaling pathway. However, such molecules associated with resistance to HER2 therapy were not identified in our gastric cancer model. This study is the first to suggest the acquired-resistance mechanism of lapatinib in HER2-positive gastric cancer.
Recent studies have shown that resistance to EGFR-TKI in nonsmall cell lung cancer cell lines is associated with EMT. EMT is linked to the loss of cell-cell adhesion, cellular elongation and invasion of the underlying ECM. EMT progression is characterized by the loss of proteins involved in cell junctions, such as E-cadherin and the claudins, and the expression of mesenchymal markers, such as Vimentin. We previously reported that TM4SF5-mediated EMT and regulation of the activity or integrity of membrane receptors including EGFR, IGF1R and/or MET on the cell surface are likely important for gefitinib resistance in cancer cells. 12 In this study, we generated novel, lapatinib-resistant, variant sublines from SNU216 parental cells by repetitive, doseescalating lapatinib treatment in vitro. Interestingly, these lapatinib-resistant lines (SNU216 LR) consist of only fibroblastlike tumor cells and show typical characteristics of EMT, such as the marked decrease in E-cadherin, increased Vimentin and Snail expression levels and increased cell motility. Moreover, using microarray analysis, we demonstrate that lapatinib-resistant cells display the upregulation of EMT-associated gene signatures. We also show that Testican-1-induced MET-dependent activation of EMT signaling occur resistant to lapatinib in a HER2-positive gastric model. Thus, we present the first EMT line of HER2-positive gastric cancer, displaying resistance to HER2-targeting agents, providing a useful in vitro model to understand the mechanism underlying the link between EMT and lapatinib resistance.
Many signaling pathways, including Wnt/b-catenin, Notch, transforming growth factor-b and MET signaling pathways, have been shown to be critical for EMT induction. The activation of Wnt/b-catenin signaling is known to regulate the expression of specific target genes and has important roles in growth and development, including the regulation of proliferation and apoptosis. Therefore, not surprisingly, alterations in b-catenin signaling are associated with tumorigenesis. Moreover, it has previously been reported that b-catenin is involved in EMT induction during tumor progression, converting polarized, epithelial cells into motile, invasive cells. In hepatocytes, b-catenin can be released from an additional membrane-bound pool associated with the MET receptor. When engaged by hepatocyte growth factor, MET releases b-catenin into the cytoplasm, leading to its eventual translocation into the nucleus. 26 Our results are consistent with these findings. On the basis of our findings, we propose that inhibition of Testican-1-induced EMT signaling may enhance response to lapatinib treatment in appropriately selected HER2-positive gastric cancer patients. In this study, the measurement of basal gene expression levels allowed us to identify Testican-1-mediated EMT as a mechanism of acquired resistance to lapatinib in HER2-gastric cancer cells. Testican-1 silencing partially restored sensitivity to lapatinib in resistant cells, implying that other signaling pathways may also be responsible for drug resistance. However, owing to the limited number of cell lines used in our experiments, it is possible that other important biological factors exist that contribute to drug resistance in HER2-positive gastric cancer.
In summary, our work demonstrates that HER2-positive gastric cancer cells that develop resistance to lapatinib may also develop cross-resistance to several other HER2-targeted agents. Acquired resistance to lapatinib was associated with EMT. Although these molecular changes may serve as molecular markers of resistance, they may also be associated with an increased invasive capacity of cancer cells in vitro. Our study may assist in understanding the mechanisms associated with acquired resistance to lapatinib, and serve to identify resistant tumors in clinical trials. SNU216 LR cells also represent a potentially useful tool for gaining insights into the mode of action of lapatinib in tumors, in addition to investigating and developing methods to prevent resistance to this drug or other targeted therapies.
MATERIALS AND METHODS

Cell culture and reagents
The SNU216 human gastric cancer cell line was obtained from the Korean Cell Line Bank (Seoul, Korea). Cells were cultured in RPMI-1640 media containing 10% fetal bovine serum (Gibco, Carlsbad, CA, USA) at 37 1C under 5% CO 2 . Lapatinib was a gift from GlaxoSmithKline (Research Triangle Park, NC, USA). Gefitinib, Afatinib, Dacomitinib and XAV-939 were purchased from Selleck Chemicals (Houston, TX, USA). Stock solutions were prepared in dimethyl sulfoxide and stored at À 20 1C.
Generation of lapatinib-resistant clones from SNU 216 cells in vitro SNU216 cells were exposed to increasing concentrations of lapatinib over a period of 8 months, reaching a final concentration of 10 mmol/l at the end of this period. Single-cell clonal populations were obtained by serial dilution or isolation with cloning cylinders. Cells were expanded in RPMI-1640 medium containing 10% fetal bovine serum containing lapatinib (1 mmol/l).
Growth inhibition assays
The viability of cells was assessed using MTT assays (Sigma-Aldrich, St Louis, MO, USA). A total of 3 Â 10 3 cells were seeded in 96-well plates, incubated for 24 h, and treated for 72 h with indicated drugs at 37 1C. Following treatment, MTT solution was added to each well and incubated for 4 h at 37 1C. The medium was then removed, and dimethyl sulfoxide was added and mixed thoroughly for 30 min at room temperature. Cell viability was determined by measuring absorbance at 540 nm using a VersaMax microplate reader (Molecular Devices, Sunnyvale, CA, USA). The concentration of drug required to inhibit cell growth by 50% was determined via interpolation from dose-response curves using Calcusyn software (Biosoft, Ferguson, MO, USA). Six replicate wells were utilized for each analysis, and at least three independent experiments were conducted. The data from replicate wells are presented as the mean number of the remaining cells with 95% confidence intervals.
Western blot and phospho-receptor tyrosine kinase Arrays Antibodies against p-EGFR (pY1068), p-HER2(pY1221/1222), p-HER3 (pY1289), p-Stat3 (pY705), p-Akt (pS473), p-MAPK (Thr202/Tyr204), EGFR, HER2, HER3, Akt, MAPK, Vimentin, E-cadherin and Axin were purchased from Cell Signaling Technology (Beverley, MA, USA). Anti-b-catenin, cyclin D and p27 antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Subconfluent cells (70-80%) were used for protein analyses. For the analysis of signaling post drug treatments, cells were treated with Testican-1-mediated EMT induced resistance to lapatinib H-P Kim et al different concentrations of lapatinib or XAV939 for 48 h and lysed in RIPA or NP40 buffer. Immunoprecipitation was performed as previously described and analyzed by western blot using an enhanced chemiluminescence system. Phospho-receptor tyrosine kinase arrays were purchased from R&D Systems (Minneapolis, MN, USA) and were conducted in accordance with the manufacturer's instructions.
Small interfering RNA knockdown
Small interfering RNA against Testican-1 was purchased from mbiotech (Seoul, Korea). Cells were transfected with small interfering RNAs (40 nmol/l) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer's instructions. Cell lysates were harvested 48 h after transfection.
Microarray analysis
Total RNA was extracted from SNU216 and SNU216 LR4 cells using an RNeasy mini kit (Qiagen, Valencia, CA, USA) in accordance with the manufacturer's instructions. RNA (xug) was hybridized on HG-U133 Affymetrix Genechip arrays (Affymetrix, Santa Clara, CA, USA) by an Agilent certified service provider (DNA Link, Seoul, South Korea). All samples were analyzed and reported according to MIAME (minimum information about a microarray experiment) guidelines. Gene expression changes in SNU216 LR4 cells compared with the SNU216 cells (X2 fold) were identified using the GeneExpress Software System Fold Change Analysis tool. For each gene fragment, the ratio of the geometric means of the expression intensities in SNU216 and SNU216 LR4 cells was calculated, and the fold change was then calculated on a per fragment basis. Confidence limits were calculated using a two-sided Welch modified t-test for the difference of the means for the logs of the intensities. 
Wound-healing assay
Cells were seeded at a high density on 60-mm culture dishes. Twelve hours later, the wounds were made by scraping through the cell monolayer with a pipette tip. After washing, the cells were incubated in growth medium for 24 h and observed under a microscope. The wound closure was estimated as the ratio of the remaining wound area relative to the initial wounded area.
Cell cycle analysis
Cells were washed twice in phosphate-buffered saline, fixed in 70% ethanol and incubated at À 20 1C, until analysis was performed. Before the analysis, cell suspensions were washed with phosphate-buffered saline, digested with RNase A (50 mg/ml) for 15 min at 37 1C and stained with propidium iodide (50 mg/ml). The DNA content (10 000 cells/experimental group) was determined using a FACSCalibur flow cytometer (Becton Dickinson Biosciences, San Jose, CA, USA) equipped with a ModFit LT program (Verity Software House Inc., Topsham, ME, USA), as previously described.
